Khanal Pukar, Patil B M
Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi, 590010 India.
J Diabetes Metab Disord. 2020 Jun 7;19(2):735-747. doi: 10.1007/s40200-020-00554-9. eCollection 2020 Dec.
Although α-amylase is the choice of target to manage postprandial hyperglycemia, inhibitors of this enzyme may get absorbed into the systemic circulation and modulate proteins involved in the pathogenesis of diabetes mellitus. Hence, the present study aimed to identify α-amylase inhibitors from via and and predict their role in the modulation of multiple pathways involved in diabetes mellitus.
α-amylase inhibitory activity of hydroalcoholic extract/fractions (s) and pure compounds from was performed using enzyme inhibitory assay. Multiple open-source databases and published literature were used to retrieve reported phytoconstituents present in and their targets. The network was constructed between α-amylase inhibitors, modulated proteins, and expressed pathways. Further, hit molecules were also confirmed for their potency to inhibit α-amylase using molecular docking and enzyme inhibitory assay. The glucose uptake assay was performed to assess the effect of hydrolcoholic extract/fraction(s) using rat hemidiaphragm.
Fraction rich in flavonoids showed the highest α-amylase inhibitory activity with a IC of 644.29 ± 4.36 µg/ml compared to other fractions. PI3K-Akt signaling pathway and p53 signaling pathway were predicted to be primarily modulated in the compound-protein-pathway network. Similarly, scutellarein was predicted as lead hit based on α-amylase inhibitory action, binding affinity, and regulated pathways. Further, α-amylase inhibitors were also predicted to modulate the pathways involved in diabetes complications like AGE-RAGE and FoxO signaling pathway. Fraction rich in flavonoids showed the highest glucose uptake in rat hemidiaphragm with an effective concentration of 534.73 ± 0.79 µg/ml.
The α-amylase inhibitors from may not be limited within the gastrointestinal tract to inhibit α-amylase but may get absorbed into the systemic circulation and modulate multiple pathways involved in the pathogenesis of diabetes mellitus to produce synergistic/additive effect.
尽管α-淀粉酶是控制餐后高血糖的首选靶点,但该酶的抑制剂可能会被吸收进入体循环,并调节参与糖尿病发病机制的蛋白质。因此,本研究旨在从[具体来源]中鉴定α-淀粉酶抑制剂,并预测它们在调节糖尿病相关多种途径中的作用。
采用[具体酶抑制试验名称]酶抑制试验,对[具体来源]的水醇提取物/馏分和纯化合物进行α-淀粉酶抑制活性测定。利用多个开源数据库和已发表的文献检索[具体来源]中报道的植物成分及其靶点。构建了α-淀粉酶抑制剂、调节蛋白和表达途径之间的网络。此外,还通过[具体分子对接软件名称]分子对接和[具体酶抑制试验名称]酶抑制试验,确认了命中分子抑制α-淀粉酶的效力。采用大鼠半膈肌葡萄糖摄取试验,评估水醇提取物/馏分的作用效果。
与其他馏分相比,富含黄酮类化合物的馏分显示出最高α-淀粉酶抑制活性,IC50为644.29±4.36μg/ml。在化合物-蛋白质-途径网络中,PI3K-Akt信号通路和p53信号通路预计主要受到调节。同样,基于α-淀粉酶抑制作用、结合亲和力和调节途径,黄芩素被预测为主要命中物。此外,α-淀粉酶抑制剂还预计会调节糖尿病并发症相关途径,如AGE-RAGE和FoxO信号通路。富含黄酮类化合物的馏分在大鼠半膈肌中显示出最高的葡萄糖摄取量,有效浓度为534.73±0.79μg/ml。
[具体来源]中的α-淀粉酶抑制剂可能不限于在胃肠道内抑制α-淀粉酶,而是可能被吸收进入体循环,并调节参与糖尿病发病机制的多种途径,产生协同/相加作用。